A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1
243
about 4 years
18+
29 sites in CA, CO, FL +15
About this study
Researchers are testing a treatment called IAM1363 to see if it's safe and effective for people with advanced cancers that have HER2 changes. The trial will involve adults, and the estimated length of it is 1467 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take IAM1363
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Confirmed central nervous system ORR (CNS-cORR), Confirmed objective response rate (cORR), Incidence and severity of adverse events (AEs), Pharmacokinetic (PK) parameters
Secondary: Best overall response (BoR) rate, Clinical benefit rate (CBR), Disease control rate (DCR), Duration of response (DoR), Overall survival (OS), Progression-free survival (PFS)
Oncology, Neurology